Abstract
Fifteen patients with chemosensitive metastatic breast cancer (MBC) underwent reduced intensity (RIST) allo-SCT between 1999 and 2006. The purpose of this single-center study was to evaluate the feasibility, safety and efficacy of this therapeutic approach. The pretransplant conditioning regimen consisted of fludarabine (25 mg/m2 at days −5 to −1) and CY (60 mg/kg at days −2, −1). Stem cells were from HLA-matched sibling donors. The treatment-related mortality was 2/15 (13%). Median PFS and OS were 144 days (43–509 days) and 303 days (122–1376 days), respectively. The 1-year PFS was 20%, and the 1-year and 2-year OS was 40 and 20%, respectively. No objective tumor responses were observed, but the relatively long PFS does suggest a graft-vs-tumor effect. Although RIST using this CY/fludarabine regimen is feasible, the efficacy in this set of patients was limited. Future clinical trials should be performed to improve the knowledge of mechanisms of antitumor effects in breast cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Thomas E, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE et al. Bone-marrow transplantation (first of two parts). N Engl J Med 1975; 292: 832.
Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE et al. Bone-marrow transplantation (second of two parts). N Engl J Med 1975; 292: 895.
Huugen D, Schouten HC, Bos GM . Advantages and limitations of (non-) myeloablative allogeneic stem cell transplantation. Neth J Med 2002; 60: 162–169.
Buffart TE, Janssen JJWM, Huijgens PC . Reduced-intensity conditioning regimens in malignant haematological diseases. Neth J Med 2005; 63: 43–51.
Mielcarek M, Martin PJ, Leisenring W, Flowers MED, Maloney DG, Sandmaier BM et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756.
Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004; 10: 178–185.
Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004; 104: 961–968.
Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005; 105: 1810–1814.
Childs RW, Clave E, Tisdale J, Plante M, Hensel N, Barrett J . Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol 1999; 17: 2044.
Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, Zhang M-J et al. Allogeneic hematopoietic cell transplantation for metastatic breast cancer. Bone Marrow Transplant 2008; 41: 537–545.
Demirer T, Barkholt L, Blaise D, Pedrazzoli P, Aglietta M, Carella AM et al. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nature Clinical Practice Oncology 2008; 5: 256–267.
Storb R, Deeg H, Farewell V, Doney K, Appelbaum F, Beatty P et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986; 68: 119–125.
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.
Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267.
Carella AM, Beltrami G, Corsetti MT, Nati S, Musto P, Scalzulli P et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet 2005; 366: 318–320.
Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, Steinberg SM et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 2004; 22: 3886–3892.
Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003; 102: 3829.
Bregni M, Dodero A, Peccatori J, Pescarollo A, Bernardi M, Sassi I et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99: 4234.
Seidman AD, O′Shaughnessy J, Misset J-L . Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer? Oncologist 2002; 7: 20–28.
Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fleskens, A., Lalisang, R., Bos, G. et al. HLA-matched allo-SCT after reduced intensity conditioning with fludarabine/CY in patients with metastatic breast cancer. Bone Marrow Transplant 45, 464–467 (2010). https://doi.org/10.1038/bmt.2009.178
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2009.178
Keywords
This article is cited by
-
Carcinomatosis lymphangitis and pleurisy after allo-SCT in two patients with secondary leukemia after breast cancer
Bone Marrow Transplantation (2012)
-
Elimination of the chemotherapy resistant subpopulation of 4T1 mouse breast cancer by haploidentical NK cells cures the vast majority of mice
Breast Cancer Research and Treatment (2011)